Endurance International Group Reports 2016 Fourth Quarter and Full Year Results
Feb 16, 2017 12:05 pm UTC| Business
Fiscal Year 2016 GAAP revenue of $1.111 billionNet loss of $81.2 millionAdjusted EBITDA of $288.4 millionCash flow from operations of $155.0 millionFree cash flow of $111.8 millionTotal subscribers on platform were...
Feb 16, 2017 12:02 pm UTC| Business
- Phase 2 Data Now Expected Ahead of Schedule in 3Q 2017 - GERMANTOWN, Md., Feb. 16, 2017 -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of central nervous system therapies...
Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
Feb 16, 2017 12:01 pm UTC| Business
- Ivosidenib (AG-120) NDA Submission for IDH1m R/R AML Planned by Year End 2017; First Phase 1 Expansion Data Expected in the Second Half of 2017 - - AG-348 Pivotal Trial Design Update Expected in the Third Quarter of...
Feb 16, 2017 12:01 pm UTC| Business
BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage...
Feb 16, 2017 12:01 pm UTC| Business
BASEL, Switzerland and WATERTOWN, Mass., Feb. 16, 2017 -- Lonza Houston, Inc., a global leader in viral gene and cell therapy manufacturing, and Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage...
Feb 16, 2017 12:01 pm UTC| Business
TEL-AVIV, Israel, Feb. 16, 2017 -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late...
Feb 16, 2017 12:01 pm UTC| Business
TEL-AVIV, Israel, Feb. 16, 2017 -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of late...